Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisition

v3.23.3
Note 4 - Acquisition
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

Note 4. Acquisition - Provisional

 

On July 1, 2023, the Company, along with Messrs. Fernandez and Barreto, exercised common stock purchase warrants and were issued common stock shares by Progressive Care. The Company exercised common stock purchase warrants on a cashless basis and was issued 402,269 common stock shares. The Company also exercised common stock purchase warrants on a cash basis and paid consideration in the amount of $506,000 and was issued 230,000 common stock shares. Mr. Fernandez exercised common stock purchase warrants on a cashless basis and was issued 211,470 common stock shares. Mr. Barreto exercised common stock purchase warrants on a cashless basis and was issued 130,571 common stock shares. At the time of exercise, all of the above common stock purchase warrants were in-the-money. After the exercise of the common stock purchase warrants, the Company and Messrs. Fernandez and Barreto collectively owned approximately 53% of Progressive Care’s voting common stock.

 

Also, on July 1, 2023, the Company, along with Messrs. Fernandez and Barreto, entered into a voting agreement whereby at any annual or special shareholders meeting of Progressive Care’s stockholders, and whenever the holders of Progressive Care’s common stock act by written consent, Messrs. Fernandez and Barreto agreed to vote all of the common stock shares (including any new shares acquired after the date of the voting agreement or acquired through the conversion of securities convertible into Common Stock) that they own, directly or indirectly, in the same manner that the Company votes its common stock and equivalents. The voting agreement is irrevocable and perpetual in term.

 

As a result of the common stock purchase warrant exercises and the entry into the voting agreement, the Company concluded that there was a change in control in Progressive Care. As of July 1, 2023, NextPlat has the right to control more than 50 percent of the voting interests in Progressive Care through the concurrent common stock purchase warrant exercises and voting agreement noted above. Beginning on July 1, 2023, the Company changed the accounting method for its investment in Progressive Care, which prior to July 1, 2023 had been accounted for as an equity method investment to consolidation under the voting interest model in FASB ASC Topic 805. Therefore, Progressive Care became a consolidated subsidiary of the Company on July 1, 2023.

 

Final purchase accounting adjustments  may be materially different from the pro forma adjustments presented in this document. Increases or decreases in the fair value of the net assets may change the amount of the purchase price allocated to goodwill and other assets and liabilities. Measurement period adjustments will be recognized prospectively. The measurement period is not to exceed 12 months from the respective dates of acquisition. 

 

Progressive Care contributed revenues of approximately $12.4 million and a net loss of approximately $1.4 million to the Company for the period from July 1, 2023 to September 30, 2023. The following unaudited pro forma summary presents consolidated information of NextPlat Corp as if the business combination had occurred on January 1, 2022. 

 

   

For the Three Months Ended September 30, 2023

   

For the Three Months Ended September 30, 2022

 
   

(Unaudited)

   

(Unaudited)

 

Revenue

  $ 15,290,000     $ 12,775,000  
                 

Earnings

  $ 4,076,000     $ (13,777,000 )

 

 

   

For the Nine Months Ended September 30, 2023

   

For the Nine Months Ended September 30, 2022

 
   

(Unaudited)

   

(Unaudited)

 

Revenue

  $ 44,071,000     $ 39,248,000  
                 

Earnings

  $ (6,219,000 )   $ (16,511,000 )

 

The Company did not have any material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings.  

 

The following table summarizes the consideration transferred to acquire a controlling interest in Progressive Care and the amounts of identified assets acquired and liabilities assumed at the acquisition date, as well as the fair value of the noncontrolling interest in Progressive Care at the acquisition date:

 

   

Purchase Price Allocation

 

Total purchase consideration

  $ 11,465,000  

Fair value of non-controlling interest

    15,957,000  

Total consideration

  $ 27,422,000  
         

Identifiable net assets acquired - Provisional:

       

Cash

  $ 7,352,000  

Accounts receivable, net

    6,478,000  

Accounts receivable, other

    506,000  

Inventory

    1,631,000  

Prepaid expenses

    220,000  

Property and equipment, net

    2,883,000  

Right of use assets, net

    405,000  

Intangible assets, net:

       

Trade name

    4,060,000  

Development technology

    2,560,000  

Pharmacy records

    8,100,000  

Other

    -  

Deposits

    39,000  

Accounts payable and accrued expenses

    (8,196,000 )

Notes payable and accrued interest - current portion

    (149,000 )

Lease liabilities - current portion

    (208,000 )

Notes payable - long term

    (1,173,000 )

Lease liabilities - long term

    (230,000 )

Net assets acquired

  $ 24,278,000  
         

Goodwill

  $ 3,144,000  

 

The total consideration is based on the fair value of Progressive Care’s common stock outstanding at July 1, 2023, which was 6,162,343 common shares outstanding and a fair market value of $4.45 per share. 

 

As a result of NextPlat obtaining control over Progressive Care, NextPlat’s previously held equity interest in Progressive Care was remeasured to fair value, resulting in a gain of approximately $6.1 million, which has been recognized in the line item “Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition” on the condensed consolidated statements of comprehensive income (loss).

 

The fair value of the noncontrolling interest of  approximately $16.0 million and the fair value of the previously held equity interest of approximately $11.5 million in Progressive Care were estimated by applying a market approach and an income approach, respectively. These fair value measurements of the noncontrolling interest and the previously held equity interest are based on significant inputs not observable in the market, and thus represent Level 3 measurements. The fair value estimates for the noncontrolling interest and the previously held equity interest are based on (1) an assumed discount rate range of 10% to 11%, (2) an assumed terminal value based on long-term sustainable growth rates ranging from 3.0% to 4.8%,(3) assumed financial multiples of reporting entities deemed to be similar to Progressive Care, and (4) assumed adjustments because of the lack of control or lack of marketability, as relevant, that market participants would consider when estimating the fair value of the noncontrolling interest and the previously held equity interest in Progressive Care.

 

The goodwill is attributable to the workforce of the acquired business and the significant synergies expected to arise after NextPlat’s acquisition of a controlling interest in Progressive Care. The goodwill is not deductible for tax purposes.